Stock Analysis

3 UK Stocks That May Be Undervalued Based On Current Estimates

Published

In recent days, the UK market has experienced turbulence, with the FTSE 100 index closing lower due to weak trade data from China, highlighting global economic challenges. As investors navigate these uncertain times, identifying stocks that may be undervalued could present opportunities for those looking to capitalize on potential market mispricings.

Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom

NameCurrent PriceFair Value (Est)Discount (Est)
Begbies Traynor Group (AIM:BEG)£0.922£1.7045.8%
National World (LSE:NWOR)£0.227£0.4549.5%
On the Beach Group (LSE:OTB)£2.495£4.9449.5%
Brickability Group (AIM:BRCK)£0.58£1.1147.6%
AstraZeneca (LSE:AZN)£116.24£219.8547.1%
Gaming Realms (AIM:GMR)£0.396£0.7244.7%
GlobalData (AIM:DATA)£2.01£3.5643.5%
Duke Capital (AIM:DUKE)£0.298£0.5747.8%
Deliveroo (LSE:ROO)£1.391£2.6146.7%
Andrada Mining (AIM:ATM)£0.024£0.04749.2%

Click here to see the full list of 52 stocks from our Undervalued UK Stocks Based On Cash Flows screener.

Here we highlight a subset of our preferred stocks from the screener.

Judges Scientific (AIM:JDG)

Overview: Judges Scientific plc designs, manufactures, and sells scientific instruments with a market cap of £474.27 million.

Operations: The company generates revenue from its Vacuum segment, which accounts for £65.40 million, and its Materials Sciences segment, contributing £70.20 million.

Estimated Discount To Fair Value: 30.2%

Judges Scientific appears undervalued, trading at £71.4 against a fair value estimate of £102.33, suggesting potential for appreciation. Despite high debt levels and significant one-off items affecting results, earnings are projected to grow significantly by 23.73% annually over the next three years, outpacing the UK market's growth rate of 14.8%. Recent board changes see Ralph Elman assuming the role of Non-Executive Chair in January 2025, potentially impacting strategic direction.

AIM:JDG Discounted Cash Flow as at Feb 2025

AstraZeneca (LSE:AZN)

Overview: AstraZeneca PLC is a biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of prescription medicines, with a market cap of approximately £180.24 billion.

Operations: The company generates its revenue primarily from the biopharmaceuticals segment, which accounts for $54.07 billion.

Estimated Discount To Fair Value: 47.1%

AstraZeneca is trading at £116.24, significantly below its estimated fair value of £219.85, highlighting potential undervaluation based on cash flows. Despite a high debt level and an unstable dividend track record, the company's earnings are forecast to grow 16.65% annually, surpassing the UK market's growth rate of 14.8%. Recent positive guidance for revenue and EPS growth in 2025 reinforces its strong financial position amidst ongoing strategic developments in oncology treatments.

LSE:AZN Discounted Cash Flow as at Feb 2025

Babcock International Group (LSE:BAB)

Overview: Babcock International Group PLC operates in the design, development, manufacture, and integration of specialist systems for aerospace, defense, and security across various regions including the UK and internationally, with a market cap of £3.08 billion.

Operations: The company's revenue segments are comprised of Land (£1.14 billion), Marine (£1.47 billion), Nuclear (£1.68 billion), and Aviation (£333.10 million).

Estimated Discount To Fair Value: 40.4%

Babcock International Group is trading at £6.11, well below its estimated fair value of £10.25, suggesting undervaluation based on cash flows. The company's earnings grew significantly last year and are forecast to grow 15.1% annually, outpacing the UK market's growth rate of 14.8%. Recent guidance upgrades for fiscal year 2025 project revenue at £4.9 billion, driven by strong performance in Nuclear and Marine sectors, reinforcing its strategic growth trajectory despite moderate revenue growth forecasts.

LSE:BAB Discounted Cash Flow as at Feb 2025

Taking Advantage

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Babcock International Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com